3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
7
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Meningeal Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Interventions
Trastuzumab
4
tucatinib
3
Capecitabine
3
fludarabine
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Cyclophosphamide
2
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
omburtamab I-131
1
gadopiclenol
1
gadobutrol
1
fludarabine phosphate
1
avelumab
1
aldesleukin
1
Spinal Puncture
1
Specimen Handling
1
Nivolumab
1
Methotrexate
1
Mesna
1
Interleukin-2
1
Blood Specimen Collection
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
patritumab deruxtecan
×
1 year
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled